XML 41 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue from Significant Partners
Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:
Year-ended December 31,
202020192018
Partner A45 %13 %40 %
Partner B17 %27 %13 %
Partner C< 10%< 10%20 %
* Except for Partner B, who represents the same customer for all three years presented, Partner A represents two different customers and Partner C represents another two different customers for the three years presented.
Schedule of Commercial License Rights
Commercial license and other economic rights consist of the following (in thousands):


December 31, 2020December 31, 2019
Gross
Adjustments(1)
NetGross
Adjustments(2)
Net
Aziyo and CorMatrix$17,696 $(9,588)$8,108 $17,696 $(5,500)$12,196 
Palvella10,000 (10,000)— 10,000 (7,492)2,508 
Selexis and Dianomi10,602 (7,731)2,871 10,602 (5,216)5,386 
     Total$38,298 $(27,319)$10,979 $38,298 $(18,208)$20,090 

(1) Amounts represent accumulated amortization to principal or research and development expenses of $21.3 million and credit loss adjustments of $6.0 million as of December 31, 2020 . Of the $6.0 million credit loss adjustments as of December 31, 2020, $5.5 million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020.
(2) Amounts represent accumulated amortization to principal or research and development expenses as of December 31, 2019.
Schedule of Disaggregation of Revenue
Royalty revenue for 2020, 2019 and 2018 are reported as below (in thousands):

Year ended December 31,
202020192018
Kyprolis$25,164 $25,046 $21,686 
Evomela6,377 5,171 5,658 
Other2,255 2,566 1,952 
PromactaN/A14,193 99,260 
$33,796 $46,976 $128,556 


The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands):

Year ended December 31,
202020192018
     Captisol$109,959 $31,489 $29,123 
Contract
     Service Revenue21,803 16,776 4,749 
     License Fees4,378 6,199 78,195 
     Milestone11,516 17,173 6,577 
     Other4,967 1,669 4,253 
$42,664 $41,817 $93,774 
Schedule of Computation of Basic and Diluted Net Income (Loss) per Share
The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):
Year Ended December 31,
 202020192018
Weighted average shares outstanding:16,185 18,995 21,160 
Dilutive potential common shares:
   Restricted stock— 43 72 
   Stock options— 719 1,125 
   Warrants associated with 2019 Notes— — 1,017 
   2019 Convertible Senior Notes— — 693 
Shares used to compute diluted income (loss) per share16,185 19,757 24,067 
Potentially dilutive shares excluded from calculation due to anti-dilutive effect8,458 8,926 2,845